SynthesisFrontiers in pharmacology2026
Efficacy and safety of Shenmai injection and Shenfu injection on postoperative cognitive dysfunction: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative cognitive dysfunction (POCD) is a common neurological complication after surgery, associated with increased adverse events and mortality. While studies suggest that Shenmai injection (SMI) or Shenfu injection (SFI) may be associated with reduce POCD, rigorous systematic reviews specifically on these two botanical drug injections are lacking. Methods: We comprehensively searched eight databases (PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, VIP, CBM) from inception to May 2025 for RCTs on SMI and SFI for POCD. Data were analyzed using RevMan 5.4. Primary outcomes were Mini-Mental State Examination (MMSE) score and POCD incidence. Secondary outcomes included serum S100β protein concentration and postoperative consciousness recovery time. Continuous outcomes used mean difference (MD) or standardized mean difference (SMD) with 95% CI; dichotomous outcomes used relative risk (RR) with 95% CI. This study was registered in INPLASY (registration number: 202470131). Results: A total of 552 records were identified, and after deduplication and screening, sixteen RCTs (N = 1,199 patients) were finally included. Both SMI and SFI were associated with statistically significant higher postoperative MMSE scores at multiple time points (all P < 0.01) and were associated with lower POCD incidence at 3 days (SMI RR 0.38; SFI RR 0.52) and 7 days (SMI RR 0.26; SFI RR 0.47). However, all included trials were at high risk of bias (lack of allocation concealment and blinding). SFI was associated with lower serum S100β at 24 h (SMD = -0.40); the effect of SMI could not be evaluated due to missing data. Both injections were associated with shorter consciousness recovery time (MD = -5.67 min, 95% CI: -6.46 to -4.87, P < 0.001). Subgroup analyses showed a trend toward reduced POCD incidence across doses. Most studies did not report detailed preparation composition or chemical characterization. Only three of the 16 included RCTs reported adverse events, and therefore no reliable safety conclusions can be drawn from the current RCT evidence. Sensitivity analysis confirmed robustness. GRADE evidence quality was low for all outcomes. Conclusion: Low-certainty evidence suggests a possible association of SMI or SFI with improved cognitive outcomes, but causality is unproven. These preliminary findings require confirmation in rigorous RCTs with proper blinding and standardized measures. Systematic Review Registration: https://inplasy.com/inplasy-2024-7-0131, identifier 202470131.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.